Vivos (RDGL) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Vivos Days Sales Outstanding?

Vivos's average Accounts Receivable for the three months ended in Dec. 2023 was $0.01 Mil. Vivos's Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Vivos's Days Sales Outstanding or its related term are showing as below:

RDGL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 111.53 Med: 137.89 Max: 164.25
Current: 146

During the past 13 years, Vivos's highest Days Sales Outstanding was 164.25. The lowest was 111.53. And the median was 137.89.

RDGL's Days Sales Outstanding is ranked worse than
89.22% of 807 companies
in the Medical Devices & Instruments industry
Industry Median: 63.94 vs RDGL: 146.00

Vivos's Days Sales Outstanding declined from Dec. 2022 (182.50) to Dec. 2023 (0.00).

Vivos Days Sales Outstanding Historical Data

The historical data trend for Vivos's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Days Sales Outstanding Chart

Vivos Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

111.53

164.25

Vivos Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															182.50	167.29	78.21	91.25	-

Competitive Comparison of Vivos's Days Sales Outstanding

For the Medical Devices subindustry, Vivos's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivos's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Vivos's Days Sales Outstanding falls into.

Vivos Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Vivos's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.011	+	0.007)	/	2 )	/	0.02	*	365
=	0.009					/	0.02	*	365
=	164.25

Vivos's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.008	+	0.007)	/	2 )	/	0	*	365 / 4
=	0.0075					/	0	*	365 / 4
=	N/A

Vivos (OTCPK:RDGL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Vivos Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Vivos's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos (RDGL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadwin Avenue, Richland, WA, USA, 99352

Website

https://www.radiogel.com

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Executives

Michael K Korenko	officer: INTERIM CEO AND PRESIDENT	6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack	officer: Interim CFO	114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle	10 percent owner	505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak	director	9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement	director	12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff	officer: Chief Financial Officer	206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust	10 percent owner	909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff	director, 10 percent owner, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford	director, 10 percent owner	6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell	director, 10 percent owner	6208 W OKANOGAN AVE, KENNEWICK WA 99336